Osiris Cleared by FDA to Begin Phase II Stem Cell Trial for the Treatment of Crohn’s Disease
Osiris Therapeutics, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin enrollment in a Phase II clinical trial to evaluate the safety and effectiveness of PROCHYMAL(TM) for the treatment of Crohn’s Disease.
Article
Breakthrough Results of Neurologix’s Gene Therapy Approach to Epilepsy Presented at American Epilepsy Society Meeting in Washington, D.C.
Neurologix, Inc. (OTCBB: NRGX) today announced results from preclinical studies, which showed that Neuropeptide Y (NPY) gene transfer reduces spontaneous seizures in an in vivo model of epilepsy as well as positively influences the fundamental biological process which leads to a chronically epileptic state.
Article
Stem Cell Therapeutics (SSS) And Medicon A/S Complete Dosing Of Patients In Phase I Study Of NTx(TM)-265
Stem Cell Therapeutics Corp. (“SCT”) is pleased to announce completion of patient dosing in the Phase I Clinical Study of SCT’s NTx(TM)-265 stroke program.
Article
Genitope Corporation Files Patents For Personalized, Therapeutic Monoclonal Antibodies To Treat Non-Hodgkin’s Lymphoma
Genitope Corporation (Nasdaq: GTOP) today announced the filing of two patents for the composition and use of a panel of monoclonal antibodies directed against specific epitopes in the variable regions of the B-cell receptor (BCR).
Article
Cytori Therapeutics Completes Collaboration with Olympus Corporation; Receives Initial $11.0 Million Payment from Olympus-Cytori Joint Venture
Cytori Therapeutics, Inc. (Frankfurt:XMPA) announced today it has formally completed its formation of the recently announced regenerative medicine collaboration it entered into with Olympus Corporation.
Article
Crucell to License PER.C6 Cell Line Technology to Vakzine Projekt Management
Crucell NV said it has agreed to license its PER.C6 human cell-line technology to German vaccine development company Vakzine Projekt Management (VPM) GmbH for use in the development of a vaccine to prevent a specific but undisclosed infectious disease, and to develop diagnostics.
Article
Cryo-Cell International (CCEL) Restructures U-Cord(R) Service To Significantly Enhance Client Value
CRYO-CELL International, Inc. (“CRYO-CELL” or the “Company”), the world’s largest U-Cord(R) stem cell bank, announced today that effective December 6, 2005, the Company has strategically restructured its U-Cord Service to improve clients’ value, increase the Company’s revenues and expand market share.
Article
HIS SpinTrapâ„¢ Columns Enable Fast and Efficient, Small-scale Isolation of Histidine-tagged Proteins
GE Healthcare has announced the availability of the His SpinTrapâ„¢, a single-use spin column designed for efficient purification of histidine-tagged proteins using a standard microcentrifuge. His SpinTrap allows direct loading of unclarified homogenized cell lysates, without the need for centrifugation or filtration of the sample.
Article
Immunology Transplantation Tolerance Study Commences
Norwood Abbey Ltd (ASX:NAL) announces that its subsidiary Norwood Immunology Ltd (AIM:NIM) has advised the commencement of the pre-clinical trial at Massachusetts General Hospital, in Boston, to determine whether tolerance to donated organ and tissue transplants can be established without the need for prolonged immuno-suppressants.
Article
California Legislators Visit BrainStorm Research Facility
The delegation visited BrainStorm’s research facility at the Felsenstein Medical Research Center of Tel-Aviv University. The visit came in the wake of a recent stem cell symposium, in which BrainStorm participated, that was hosted by the Cedars-Sinai Stem Cell Initiative in Los Angeles and that was aimed at promoting cooperation among California and Israeli stem cell companies.
Article
Invitrogen Announces Realignment to Move Closer to Customers; John ‘Kip’ Miller Signs on to Lead One of Several New Focus Areas
Effective January 1, 2006, the company will create three new divisions under the traditional BioDiscovery and BioProduction business segments: Life Sciences, Bio-Production Systems and Services, and Enabling Technologies. Each of the divisions will have dedicated manufacturing, research and development, and marketing functions.
Article
Xcyte Receives Notice of Non-compliance with Nasdaq Continued Listing Standard
On December 6, 2005 Xcyte Therapies, Inc. (Xcyte, the “Company”) (Nasdaq XCYT, XCYTP) received notice from The Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 4450(a)(5) (the “Minimum Bid Price Rule”), and as a result the Company’s common stock will be delisted at the opening of business on December 15, 2005 unless the Company’s requests a hearing in accordance with the Nasdaq Marketplace Rules.
Article